Skip to content
ISSN: 1792-7110
HAEMA
The Journal of the Hellenic Society of HAEMATOLOGY
  • HOME
  • ABOUT
    • JOURNAL INFORMATION
    • EDITORIAL BOARD
  • CURRENT ISSUE
  • AUTHORS
  • ARCHIVE
    • VOLUME 15 (2024)
      • HAEMA 2024 (Suppl 1)
    • VOLUME 14 (2023)
      • HAEMA 2023 (1-4)
      • HAEMA 2023 (Suppl 1)
    • VOLUME 13 (2022)
      • HAEMA 2022 (1-2)
      • HAEMA 2022 (Suppl 1)
    • VOLUME 12 (2021)
      • HAEMA 2021 (1)
      • HAEMA 2021 (Suppl 1)
    • VOLUME 11 (2020)
      • HAEMA 2020 (Suppl 1)
    • VOLUME 10 (2019)
      • HAEMA 2019 (1)
      • HAEMA 2019 (2)
      • HAEMA 2019 (Suppl 1)
    • VOLUME 9 (2018)
      • HAEMA 2018 (Suppl 1)
    • VOLUME 8 (2017)
      • HAEMA 2017 (1)
      • HAEMA 2017 (2)
      • HAEMA 2017 (4)
    • VOLUME 7 (2016)
      • HAEMA 2016 (1)
      • HAEMA 2016 (2)
      • HAEMA 2016 (3)
      • HAEMA 2016 (4)
    • VOLUME 6 (2015)
      • HAEMA 2015 (4)
    • VOLUME 5 (2014)
      • HAEMA 2014 (1)
      • HAEMA 2014 (4)
    • VOLUME 4 (2013)
      • HAEMA 2013 (1)
      • HAEMA 2013 (2)
      • HAEMA 2013 (3)
      • HAEMA 2013 (4)
    • VOLUME 3 (2012)
      • HAEMA 2012 (1)
      • HAEMA 2012 (2)
      • HAEMA 2012 (3)
      • HAEMA 2012 (4)
    • VOLUME 2 (2011)
      • HAEMA 2011 (2)
      • HAEMA 2011 (3)
      • HAEMA 2011 (4)
    • VOLUME 1 (2010)
      • HAEMA 2010 (1)
      • HAEMA 2010 (2)
      • HAEMA 2010 (4)
  • SUBMIT YOUR MANUSCRIPT
  • CONTACT US

33rd Congress of the Hellenic Society of Haematology

Posted on November 8, 2022December 22, 2022 by admin

Haema 2022; 13(Suppl 1)

CONGRESS PROCEEDINGS

Full PDF (in Greek) |

Posted in HAEMA 2022 (Suppl 1)
Post navigation
Prognostic Significance of IDH1 and IDH2 Mutations in Greek Patients with Newly Diagnosed AML →
← 34rd Congress of the Hellenic Society of Haematology

SEARCH

CURRENT ISSUE

Post of 64th American Society of Hematology (ASH) Annual Meeting, December 10-13, 2022 New Orleans, USA

Post ASH 2022: Acute Myeloid Leukemia

Post ASH 2022: Paroxysmal Nocturnal Hemoglobinuria and thrombotic microangiopathies

Post ASH 2022: Key studies in chronic lymphocytic leukemia (CLL)

Post ASH 2022: Mantle cell and low grade B-Cell Lymphomas

Post ASH 2022: Hodgkin lymphoma, what’ new?

Post ASH 2022: High-grade B-cell Lymphomas, what’s new?

Post ASH 2022: Hemoglobinopathies

  • About Us

    HAEMA is the official journal of the Hellenic Society of Hematology. HAEMA was founded in March 1998, since when it has been published regularly and has undergone several modifications,in both the language (Greek-English) and the content of the journal.
    The new edition of HAEMA is an English language, independent, open-access, peer reviewed journal, published quarterly.

  • FIND ARTICLE BY KEYWORD

    Acalabrutinib (1) Acute myeloid leukemia (1) Acute myeloid leukemia (AML) (2) AML (1) Azacitidine (2) bcl-2 inhibitors (1) bispecific antibodies (1) brentuximab vedotin (1) bruton kinase inhibitors (1) CAR-T cells (2) CAR T-cell therapies (1) chronic lymphocytic leukemia (1) Clinical trials (1) cold-agglutinin disease (1) complement (1) ctDNA (1) DLBCL (2) favezelimab (1) Follicular lymphoma (1) frontline treatment (1) Hemoglobinopathy (1) high risk disease (2) Hodgkin lymphoma (2) ibrutinib (1) IDH1/IDH2 mutations (1) intensive chemotherapy (2) International Consensus Classification (ICC) 2022 (2) magrolimab (2) Mechanism of action (1) nivolumab (1) novel agents (1) Paroxysmal nocturnal hemoglobinuria (1) pembrolizumab (1) pirtobrutinib (1) Prognosis (2) prognostic factors (1) sickle cell disease (1) thalassemia (1) thrombotic microangiopathies (1) Thrombotic microangiopathy (1) Thrombotic thrombocytopenic purpura (2) Treatment (2) Venetoclax (4) WHO 2022 Classification (2) zanubrutinib (1)
Theme by Out the Box